The Medicines Company

Most Recent

  • uploads///AdobeStock_
    Consumer

    Where Stanley Druckenmiller Is Bullish

    Last week, Duquesne Family Office, managed by Stanley Druckenmiller, filed its Q3 13F with the SEC. We’ll look at the fund’s top holdings, buys, and sells.

    By Rabindra Samanta
  • uploads///ALNY
    Earnings Report

    What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates

    Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///PRODUCTS AND PIPELINE
    Company & Industry Overviews

    A Look at Mylan’s Launch of Its Generic Angiomax Injection

    On June 1, Mylan (MYL) announced the launch of a generic version of the Medicines Company’s (MDCO) Angiomax, which is bivalirudin.

    By Sarah Collins
  • uploads///Branded Rx prod
    Company & Industry Overviews

    Behind Valeant’s Branded Drugs: Other 3Q17 Performances

    In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Vabomere: Major Addition to The Medicines Company’s Portfolio?

    On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inclisiran: Long-Term Growth Driver for The Medicines Company?

    According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    The Medicines Company May Report Steep Revenue Decline in 2017

    In 2Q17, The Medicines Company (MDCO) reported a net loss from continuing operations of $397.3 million, which was a significant fall from $181.8 million in 2Q16.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for The Medicines Company in October

    In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Mid-Caps: Medicines Company’s Carbavance, Fast-Track Status

    In a press release, the Medicines Company (MDCO) announced that the FDA has granted fast-track status to Carbavance for the treatment of complicated urinary tract infections.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Small-Caps Are Topping the IBB Portfolio

    Biotech stocks and ETFs had a good day on December 21 and rose marginally. The iShares Nasdaq Biotechnology ETF (IBB) rose 0.2% for the day and closed at $332.13.

    By Peter Neil
  • uploads///Chart
    Macroeconomic Analysis

    The PowerShares Dynamic Pharmaceuticals ETF: PJP’s 2015 Performance

    As of November 2015, PJP has outperformed the market, with a YTD return of 6.5%. The fund’s top ten holdings represent 52.41% of its total portfolio.

    By Ivan Kading
  • uploads///Graph Part
    Company & Industry Overviews

    Performance of XBI and IBB with Respective Benchmark Indexes

    The SPDR S&P Biotech ETF (XBI) fell 4.53%. It tracks the S&P Biotechnology Select Industry Index as its benchmark index, which fell 4.32% for the week ended September 4.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.